growth somewhat murki ahead guid
provid guidanc novemb compani mix
headwinds/tailwind need pars mani non-oper
oper side outlook mwi outsiz growth question given recent
volatil across anim health market also tough cost comp deal
benefit vast major hd smith synergi
strong expens manag may recur one-tim benefit relat
healthcar benefit expens taken togeth remain street expect
initi guid even assumpt build addit share repurchas
contribut tweak ep ep
mostli buy-back assumpt reiter under-perform
rate price object equat ep
outlook brand gener inflat appear stabl compar past two
year brand inflat settl mid-singl digit rang gener trend
continu move steadi direct least regard distributor spread
elect come focu recent hous drug price plan indic
democrat republican like make prescript cornerston
healthcar talk point could weigh pace price chang
think one factor continu limit long-term earn power
visibl distributor addit opioid tail risk remain major uncertainti
believ constrain abc multipl near-term particularli
consid trade premium group normal exclus
opioid-rel litig cost vs inclus cah/mck actual modestli higher
report distributor overhang potenti
type global opioid settlement remain nebul rel visibl
net dbt
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one largest drug distributor us
sizabl global gener sourc joint ventur
partnership
anim health unit oper
companion product anim distribut
transport logist technolog
compani base chesterbrook pa
under-perform rate driven uncertainti
on-going pharmedium closur creat
addit margin drag see concern
profit squeez across pharma suppli chain
subsector would expect distributor like
whose pharmaci struggl
reimburs pressur feel
squeez addit expect
continu premium cah/mck see
spread close
benefit could headwind
benefit multipl non-repeat item includ hd smith
synergi one-tim healthcar benefit gain strong expens previous
estim accret smith estim vast
major recogn compani also captur coupl penni
healthcar benefit relat cost like add
repeat separ guid msd opex growth
cost increas high-end msd back half year
howev expens growth first three quarter remain low
singl digit rang suggest oper leverag may prove difficult
exhibit consensu ep histori tick back-up steadi reduct cours
price object base ep multipl
five-year averag five-year high although would argu
artifici high due period gener inflat also repres bigger
discount vs last five year think discount warrant given
incorpor modest growth slowdown seen rest suppli
chain well encompass competit risk
upsid risk po potenti volum pickup increas buyside/sellsid
spread opportun cost save deepen relationship
walgreen largest custom downsid risk po increment wors
drug price pressur increas competit creat gross profit headwind risk
amazon anoth disrupt forc enter suppli chain market on-going
uncertainti headlin relat opioid litig process lack avail
attract capit deploy opportun uncertainti across market
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
